(3aS,4S,6aR)-2,2-dimethyl-tetrahydrocyclopenta[d][1,3]dioxol-4-ol | 877651-72-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3aS,4S,6aR)-2,2-dimethyl-tetrahydrocyclopenta[d][1,3]dioxol-4-ol
• 英文别名: (3aS,4S,6aR)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-ol；(3aS,4S,6aR)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol；(3aS,4S,6aR)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol
• CAS: 877651-72-4
• 化学式: C₈H₁₄O₃
• 分子量: 158.197
• InChiKey: PSOOETMCZCWPBV-XVMARJQXSA-N

物化性质

• 沸点：
  248.0±20.0 °C(Predicted)
• 密度：
  1.126±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3aS,4S,6aR)-2,2-dimethyl-tetrahydrocyclopenta[d][1,3]dioxol-4-ol 在 正丁基锂 、 偶氮二甲酸二异丙酯 、 氨 、 二异丙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 为溶剂， 反应 99.5h， 生成 9-((3aS,4R,6aR)-tetrahydro-2,2-dimethyl-3aH-cyclopenta[d][1,3]dioxol-4-yl)-8-methyl-9H-purin-6-amine
  参考文献：
  名称：

  Aristeromycin、Neplanocin、3-Deazaneplanocin 和相关类似物的 8-甲基衍生物

  摘要：

  The promising biological properties of 8-methyladenosine prompted a study of the related carbocyclic analogs based on aristeromycin and neplanocin. These target compounds have been prepared from strategically protected parent carbocyclic nucleoside derivatives or built up from suitable cyclopentanols and cyclopentenols. Several of these nucleosides were evaluated against a variety of RNA and DNA viruses to determine the potential of the 8-methyl series as a source for new antiviral agents. Encouraging results towards Epstein-Barr virus, cowpox, vaccinia virus, Ebola, and the flaviviruses (dengue and yellow fever) suggests more extensive studies.

  DOI：

  10.3987/com-16-s(s)36
• 作为产物：
  描述：

  (3AS,4S,6AR)-2,2-二甲基-3A,6A-二氢-4H-环戊[D][1,3]二噁酚-4-醇 在 palladium 10% on activated carbon sodium tetrahydroborate 、 氢气 作用下， 以 甲醇 为溶剂， 反应 0.08h， 生成 (3aS,4S,6aR)-2,2-dimethyl-tetrahydrocyclopenta[d][1,3]dioxol-4-ol
  参考文献：
  名称：

  AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA

  摘要：

  本发明涉及式(I)的AHCY抑制剂，对于治疗高同型半胱氨酸水平疾病（如阿尔茨海默病）具有益处。该发明还涉及包含这些化合物的药物组合物，以及在治疗高同型半胱氨酸水平疾病中使用这些化合物和组合物。

  公开号：

  US20110160229A1

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK<br/>[FR] COMPOSÉS ET COMPOSITIONS UTILES POUR TRAITER DES TROUBLES ASSOCIÉS AU GÈNE NTRK
  申请人：BLUEPRINT MEDICINES CORP

  公开号：WO2017035354A1

  公开（公告）日：2017-03-02

  This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.

  这项发明涉及对NTRK的抑制剂，对野生型NTRK及其耐药突变体具有活性。
• The Mitsunobu reaction in preparing 3-deazapurine carbocyclic nucleosides
  作者：Minmin Yang、Jian Zhou、Stewart W. Schneller

  DOI：10.1016/j.tet.2005.10.052

  日期：2006.2

  The coupling reaction of 4-chloro-1H-imidazo[4,5-c]pyridine (6-chloro-3-deazapurine, 3) with several cyclopentyl derivatives under Mitsunubo reaction conditions provides an efficient entry into N-7 and N-9 substituted 3-deazapurine carbocyclic nucleosides of antiviral potential. The versatility of this procedure is illustrated with a new and efficient synthesis of (−)-3-deazaaristeromycin, a formal

  在Mitsunubo反应条件下，4-氯-1 H-咪唑并[4,5- c ]吡啶（6-氯-3-去氮杂嘌呤，3）与几种环戊基衍生物的偶联反应可有效地进入N-7和N- 9个具有抗病毒潜力的3-deazapurine碳环核苷取代基。该程序的多功能性通过（-）-3-deazaaristeromycin的新型有效合成，3-deazaneplanocin A的正式制备以及通往3-deaza-5'-homoaristeromycin的途径得以说明。
• [EN] AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA<br/>[FR] INHIBITEURS D'HYDROLASE DE AHCY POUR LE TRAITEMENT DE L'HYPERHOMOCYSTÉINÉMIE
  申请人：MERCK SHARP & DOHME

  公开号：WO2010027935A1

  公开（公告）日：2010-03-11

  The present invention is directed to AHCY inhibitors of formula (I): which are useful in the treatment of diseases characterized by high homocysteine levels, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases characterized by high homocysteine levels.

  本发明涉及式(I)的AHCY抑制剂，其在治疗高同型半胱氨酸水平的疾病，如阿尔茨海默病中有用。本发明还涉及包含该化合物的制药组合物，以及在治疗高同型半胱氨酸水平的疾病中使用该化合物和组合物的用途。
• AHCY hydrolase inhibitors for treatment of hyper homocysteinemia
  申请人：Converso Antonella

  公开号：US08629275B2

  公开（公告）日：2014-01-14

  The present invention is directed to AHCY inhibitors of formula (I): which are useful in the treatment of diseases characterized by high homocysteine levels, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases characterized by high homocysteine levels.

  本发明涉及公式(I)的AHCY抑制剂，其可用于治疗高同型半胱氨酸水平的疾病，如阿尔茨海默病。本发明还涉及包含该化合物的制药组合物，以及在治疗高同型半胱氨酸水平的疾病中使用该化合物和组合物的方法。
• Compounds and compositions useful for treating disorders related to NTRK
  申请人：BLUEPRINT MEDICINES CORPORATION

  公开号：US10017512B2

  公开（公告）日：2018-07-10

  This disclosure relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants, such as compounds of Formula (I):

  本公开涉及对野生型 NTRK 及其抗性突变体有活性的 NTRK 抑制剂，如式 (I) 化合物：